Skip to content

Clinical observation of "Tongjiao Sanjiao" acupuncture combined with needle-embedding therapy to improve diabetic neurogenic bladder

Clinical observation of "Tongjiao Sanjiao" acupuncture combined with needle-embedding therapy to improve diabetic neurogenic bladder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001166
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic neurogenic bladder

Interventions

Treatment group:On the basis of the control group "Tongjiao Sanjiao" acupuncture combined with needle-embedding therapy was added
Control group:Oral mecobalamine tablets + lipoic acid tablets

Sponsors

Shanghai Yangpu Daqiao Community Health Service Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-75 years old gender is not limited; (2) It meets the diagnostic criteria of Western medicine for type 2 diabetes and diabetic neurogenic bladder. The purpose of this study was to observe the influence of traditional Chinese medicine therapy on the early stage of diabetic neurogenic bladder disease so the criteria for inclusion of cases required bladder residual urine volume =50ml =200ml; (3) consistent with the traditional Chinese medicine diagnosis of spleen-kidney deficiency syndrome of Xiaokeying; (4) Voluntarily cooperate and agree to treat patients and sign the informed consent to enter the study.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant planning to become pregnant or breastfeeding; (2) neurogenic bladder caused by other causes (central drug alcohol iatrogenic etc.); (3) Patients with serious visceral diseases or other serious primary diseases or mental disorders; (4) infectious diseases such as bodily fluid transmission and contact transmission and serious urinary tract infections; (5) Bleeding or bleeding tendency in the past 2 months; (6) People with allergies; Those who do not cooperate or cannot comply with the treatment plan; (7) Participants who have participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
Urodynamic measures;

Secondary

MeasureTime frame
TCM syndrome score;American Urological Association Symptom Index;SF-Qualiveen questionnaire short form score;

Countries

China

Contacts

Public ContactWang Jinxiang

Shanghai Yangpu Daqiao Community Health Service Center

1193794198@qq.com15221191269

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026